Author:
Goldenberg David M.,Sharkey Robert M.
Publisher
Springer Berlin Heidelberg
Reference165 articles.
1. Aarts F, Bleichrodt RP, Oyen WJ, Boerman OC (2008) Intracavitary radioimmunotherapy to treat solid tumors. Cancer Biother Radiopharm 23:92–107
2. Alvarez RD, Partridge EE, Khazaeli MB et al (1997) Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 65:94–101
3. Alvarez RD, Huh WK, Khazaeli MB et al (2002) A Phase I study of combined modality 90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 8:2806–2811
4. Andersson H, Cederkrantz E, Back T et al (2009) Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab’)2–a phase I study. J Nucl Med 50:1153–1160
5. Bale WF, Spar IL (1957) Studies directed toward the use of antibodies as carriers of radioactivity for therapy. Adv Biol Med Phys 5:285–356